A bad day for Valeant is coming sooner than expected, and the stock is falling (VRX)
The FDA has approved a generic version of Valeant Pharmaceuticals' heart drug Nitropress, according to its website, and shares of Valeant are down almost 5% on the news.
Читать дальше...